Key facts
- It has raised $3.7M; the latest was Seed Round ($2.8M) in Apr 2025.
- Notable investors include High-Tech Gründerfonds, Vorwerk Ventures.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Carelane
- ·The full record, as it builds
Funding rounds
No funding rounds for Carelane are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Carelane
Developer of a clinical research platform designed to streamline the entire clinical trial process from study design to analysis. The company's platform offers a comprehensive suite of tools including study authoring, site management, participant tracking, advanced data governance, and real-time analytics, enabling researchers, health systems, and biopharma companies to efficiently conduct clinical trials, reduce operational costs, and improve data quality across multiple locations and study phases.
- Sector
- Healthcare
- HQ
- Bremen, Germany
- Founded
- 2023
- Employees
- 6
- Website
- carelane.io/
- Ownership
- Privately Held (backing)
Carelane doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Carelane shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Carelane in its N-PORT filings yet. We sweep new filings monthly.